Results 31 to 40 of about 85,679 (96)

Ferulic acid reduces GLP‐1 degradation to ameliorate diet‐induced obesity‐associated hepatic steatosis

Food Frontiers
GLP‐1 is a vital candidate for stimulating insulin secretion in a glucose‐dependent manner, reducing body weight and eliminating nonalcoholic fatty liver disease with few side effects.
Yuxuan An, Lichao Zhang, Xiaxia Fan, Kaili Cui, Shuiling He, Pengyu Ji, Jinmiao Tian, Zhuoyu Li   +7 more
doaj   +1 more source

GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation

Cardiovascular Diabetology, 2020
Background Glucagon-like peptide-1 (GLP-1) induces diuresis and natriuresis. Previously we have shown that GLP-1 activates afferent renal nerve to increase efferent renal sympathetic nerve activity that negates the diuresis and natriuresis as a negative ...
Kenichi Katsurada, Shyam S. Nandi, Hong Zheng, Xuefei Liu, Neeru M. Sharma, Kaushik P. Patel   +5 more
doaj   +1 more source

GLP-1 based therapeutics: Simultaneously combating T2DM and obesity

Frontiers in Neuroscience, 2015
Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor (GLP-1R) in the brain to suppress feeding. These combined actions of GLP-
Kristy M Heppner, Diego ePerez-Tilve
doaj   +1 more source

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes

BMJ Open Diabetes Research & Care, 2020
ObjectiveGlucagon receptor (GCGR) blockage improves glycemic control and increases circulating glucagon-like peptide-1 (GLP-1) level in diabetic animals and humans.
Shan Lang, Liangbiao Gu, Xiaona Cui, Tianjiao Wei, Junling Liu, Yunyi Le, Rui Wei, Tianpei Hong   +7 more
doaj   +1 more source

Estrogenic activity of E2-conjugated GLP-1 is mediated by intracellular endolysosomal acidification and estrone metabolism

Molecular Metabolism
Objective: Recent modifications to glucagon-like peptide 1 (GLP-1), known for its insulinotropic and satiety-inducing effects, have focused on conjugating small molecules to enable selective delivery into GLP-1R+ tissues to achieve targeted synergy and ...
Callum Coupland, Na Sun, Ahmed Khalil, Özüm Ezgi Karaoglu, Arkadiusz Liskiewicz, Daniela Liskiewicz, Gerald Grandl, Seun Akindehin, Gandhari Maity, Bin Yang, Brian Finan, Patrick Knerr, Jonathan D. Douros, Axel Walch, Richard DiMarchi, Matthias H. Tschöp, Timo D. Müller, Aaron Novikoff   +17 more
doaj   +1 more source

GLP‐1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions

Clinical and Translational Science
Glucagon‐like peptide‐1 agonists (GLP‐1A) are increasingly prescribed to treat obesity and type 2 diabetes mellitus in children and adolescents.
Michael Bartkoski, Ethan A. Poweleit, Stephani L. Stancil   +2 more
doaj   +1 more source

Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer

Frontiers in Pharmacology
Background: Glucagon-like peptide-1 (GLP-1) has crucial impact on glycemic control and weight loss physiologically. GLP-1 receptor agonists have been approved for treatment of diabetes and obesity.
Chaojun Zhu, Yihong Lai, Chengdong Liu, Lan Teng, Yuxin Zhu, Xinyu Lin, Xinyi Fu, Qiuhua Lai, Side Liu, Side Liu, Xiaohan Zhou, Yuxin Fang   +11 more
doaj   +1 more source

GLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?

Diabetology
Incretin hormones, such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are essential regulators of glucose homeostasis, energy balance, and metabolic communication between organs.
Grazia Piras, Sara Brasili, Davide Demontis, Leonardo Della Sala, Francesco Cocchiara, Davide Carlo Maggi, Anna Arecco   +6 more
doaj   +1 more source

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation

Frontiers in Immunology
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a cornerstone in the treatment of diabetes and obesity and have emerged as a promising option for other metabolic disorders, including hepatic steatosis.
Giulia Migliorisi, Giulia Migliorisi, Roberto Gabbiadini, Arianna Dal Buono, Matteo Ferraris, Matteo Ferraris, Giuseppe Privitera, Giuseppe Privitera, Lorenzo Petronio, Lorenzo Petronio, Peter Bertoli, Peter Bertoli, Cristina Bezzio, Cristina Bezzio, Alessandro Armuzzi, Alessandro Armuzzi   +15 more
doaj   +1 more source

Intestinal interleukin-22 enhances GLP-1 production via the STAT3 pathway to improve glucose homeostasis during high-fat diet induced obesity in a study with male mice

Nature Communications
Metabolic disorders such as obesity and diabetes are influenced by glucagon-like peptide-1 (GLP-1), which regulates insulin secretion. Interleukin (IL)−22 maintains intestinal barrier function, yet its role in metabolic regulation remains unclear.
Chae-Won Kim, Jae-Hee Ahn, Bo Ra Lee, Hong Min Kim, Youngjoo Han, Jae-Hyeon Jeong, Jaewon Cho, Hyunjin Jeong, Dae-Joon Kim, Seong-Eun Kim, Jeon-Kyung Kim, Yu-Bin Lee, Su Min Kim, Hye Hyun Yoo, Eun Hye Lee, Su Ryeon Seo, Kyung Bong Ha, Eun Soo Lee, Mi-Na Kweon, Hong Pyo Kim, Sun-Young Chang, Choon Hee Chung, Hyun-Jeong Ko   +22 more
doaj   +1 more source